Amobarbital

DB01351

small molecule approved illicit

Deskripsi

A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)

Struktur Molekul 2D

Berat 226.2722
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of amobarbital.
  • 2. Take on an empty stomach. Taking oral amobarbital sodium on an empty stomach increases the rate of absorption.

Interaksi Obat

1329 Data
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Amobarbital.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Amobarbital.
Buprenorphine Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Hydrocodone Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Magnesium sulfate The therapeutic efficacy of Amobarbital can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Amobarbital may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Mirtazapine Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Orphenadrine Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Pramipexole Amobarbital may increase the sedative activities of Pramipexole.
Ropinirole Amobarbital may increase the sedative activities of Ropinirole.
Rotigotine Amobarbital may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Amobarbital.
Suvorexant Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Thalidomide Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Amobarbital.
Mefloquine The therapeutic efficacy of Amobarbital can be decreased when used in combination with Mefloquine.
Orlistat Orlistat can cause a decrease in the absorption of Amobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetaminophen The metabolism of Acetaminophen can be increased when combined with Amobarbital.
Propacetamol The metabolism of Propacetamol can be increased when combined with Amobarbital.
Chloramphenicol The metabolism of Amobarbital can be decreased when combined with Chloramphenicol.
Doxycycline The serum concentration of Doxycycline can be decreased when it is combined with Amobarbital.
Felbamate The serum concentration of Amobarbital can be increased when it is combined with Felbamate.
Griseofulvin The serum concentration of Griseofulvin can be decreased when it is combined with Amobarbital.
Lamotrigine The serum concentration of Lamotrigine can be decreased when it is combined with Amobarbital.
Mianserin The therapeutic efficacy of Amobarbital can be decreased when used in combination with Mianserin.
Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Amobarbital.
Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amobarbital.
Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Amobarbital.
Pyridoxine The metabolism of Amobarbital can be increased when combined with Pyridoxine.
Teniposide The serum concentration of Teniposide can be decreased when it is combined with Amobarbital.
Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Amobarbital.
Voriconazole The serum concentration of Voriconazole can be decreased when it is combined with Amobarbital.
Topotecan Amobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Amobarbital.
Sodium oxybate Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Amobarbital.
Perampanel The metabolism of Perampanel can be increased when combined with Amobarbital.
Warfarin The metabolism of Warfarin can be increased when combined with Amobarbital.
Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Amobarbital.
(R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Amobarbital.
R,S-Warfarin alcohol The metabolism of R,S-Warfarin alcohol can be increased when combined with Amobarbital.
S,R-Warfarin alcohol The metabolism of S,R-Warfarin alcohol can be increased when combined with Amobarbital.
(S)-Warfarin The metabolism of (S)-Warfarin can be increased when combined with Amobarbital.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Amobarbital.
Aminophylline The therapeutic efficacy of Amobarbital can be decreased when used in combination with Aminophylline.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Amobarbital is combined with Botulinum toxin type A.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Amobarbital is combined with Botulinum toxin type B.
Meperidine Amobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Somatostatin The risk or severity of adverse effects can be increased when Somatostatin is combined with Amobarbital.
Ethanol Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
Fluvoxamine The risk or severity of adverse effects can be increased when Amobarbital is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Amobarbital is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Amobarbital is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Amobarbital is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Amobarbital is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Amobarbital is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Amobarbital is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Amobarbital is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Amobarbital is combined with Dapoxetine.
Desvenlafaxine The risk or severity of adverse effects can be increased when Amobarbital is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Amobarbital is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Amobarbital is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Amobarbital is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Amobarbital is combined with Alaproclate.
Naltrexone The risk or severity of adverse effects can be increased when Amobarbital is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Amobarbital is combined with Bezitramide.
Morphine The risk or severity of adverse effects can be increased when Amobarbital is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Amobarbital is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Amobarbital is combined with Hydromorphone.
Oxycodone The risk or severity of adverse effects can be increased when Amobarbital is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Amobarbital is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Amobarbital is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Amobarbital is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Amobarbital is combined with Sufentanil.
Nalbuphine The risk or severity of adverse effects can be increased when Amobarbital is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Amobarbital is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Amobarbital is combined with Remifentanil.
Diphenoxylate The risk or severity of adverse effects can be increased when Amobarbital is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Amobarbital is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Amobarbital is combined with Dezocine.
Methadyl acetate The risk or severity of adverse effects can be increased when Amobarbital is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Amobarbital is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Amobarbital is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Amobarbital is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Amobarbital is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Amobarbital is combined with Dextromoramide.

Target Protein

Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1
Gamma-aminobutyric acid receptor subunit alpha-2 GABRA2
Gamma-aminobutyric acid receptor subunit alpha-3 GABRA3
Gamma-aminobutyric acid receptor subunit alpha-4 GABRA4
Gamma-aminobutyric acid receptor subunit alpha-5 GABRA5
Gamma-aminobutyric acid receptor subunit alpha-6 GABRA6
Neuronal acetylcholine receptor subunit alpha-4 CHRNA4
Neuronal acetylcholine receptor subunit alpha-7 CHRNA7
Glutamate receptor 2 GRIA2
Glutamate receptor ionotropic, kainate 2 GRIK2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15381635
    Kim HS, Wan X, Mathers DA, Puil E: Selective GABA-receptor actions of amobarbital on thalamic neurons. Br J Pharmacol. 2004 Oct;143(4):485-94. Epub 2004 Sep 20.
  • PMID: 5855308
    Maynert EW: The alcoholic metabolites of pentobarbital and amobarbital in man. J Pharmacol Exp Ther. 1965 Oct;150(1):118-21.
  • PMID: 684279
    Tang BK, Kalow W, Grey AA: Amobarbital metabolism in man: N-glucoside formation. Res Commun Chem Pathol Pharmacol. 1978 Jul;21(1):45-53.
  • PMID: 3437019
    Soine PJ, Soine WH: High-performance liquid chromatographic determination of the diastereomers of 1-(beta-D-glucopyranosyl)amobarbital in urine. J Chromatogr. 1987 Nov 27;422:309-14.
  • PMID: 1489761
    McCall WV: The addition of intravenous caffeine during an amobarbital interview. J Psychiatry Neurosci. 1992 Nov;17(5):195-7.

Contoh Produk & Brand

Produk: 7 • International brands: 2
Produk
  • Amytal Sodium
    Injection, powder, lyophilized, for solution • 0.5 g/5mL • Intramuscular; Intravenous • US
  • Amytal Sodium
    Injection, powder, lyophilized, for solution • 0.5 g/5mL • Intramuscular; Intravenous • US
  • Amytal Sodium 500mg
    Powder, for solution • 500 mg / amp • Intramuscular; Intravenous • Canada • Approved
  • Amytal Sodium Cap 60mg
    Capsule • 60 mg / cap • Oral • Canada • Approved
  • Amytal Sodium Pulvule 222 0.2gm
    Capsule • 200 mg / cap • Oral • Canada • Approved
  • Tuinal Pulvule 303
    Capsule • - • Oral • Canada • Approved
  • Tuinal Pulvule 304
    Capsule • - • Oral • Canada • Approved
International Brands
  • Amytal
  • Isomytal

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul